Appendix Table 11.
Probability each of the 15 treatments (ie, 5 single treatments plus 10 combinations of active treatments) for management of COPD is best, obtained on the basis of the additive main effects model considered in our secondary MTC analysis. This table includes previously unpublished roflumilast data (M2-111 trial)28
| Treatment | Probability treatment is best |
|---|---|
| Placebo | 0.000 |
| Roflumilast | 0.000 |
| LABA | 0.000 |
| LAMA | 0.000 |
| ICS | 0.000 |
| Roflumilast + LABA | 0.000 |
| Roflumilast + LAMA | 0.000 |
| Roflumilast + ICS | 0.000 |
| LABA + LAMA | 0.000 |
| LABA + ICS | 0.000 |
| LAMA + ICS | 0.000 |
| Roflumilast + LABA + LAMA | 0.000 |
| Roflumilast + LABA + ICS | 0.000 |
| LAMA + LABA + ICS | 0.003 |
| Roflumilast + LABA + LAMA + ICS | 0.997 |
Abbreviations: COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroids; LABA, long-acting beta agonists; LAMA, long-acting antimuscarinic drugs; MTC, mixed-treatment comparison.